DARPP-32 increases interactions between epidermal growth factor receptor and ERBB3 to promote tumor resistance to gefitinib

Gastroenterology

Volumn 141, Issue 5, 2011, Pages 1738-1748.e2

  Zhu, Shoumin ^a   Belkhiri, Abbes ^a   El Rifai, Wael ^a  

^a VANDERBILT INGRAM CANCER CENTER   (United States)

Author keywords

AKT; Dopamine Signaling; Drug Resistance; PI3K; PPP1R1B; Stomach Cancer; Treatment

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 3; GEFITINIB; LIPOCORTIN 5; PHOSPHOPROTEIN DARPP 32; PROTEIN KINASE B;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL SURVIVAL; CONTROLLED STUDY; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOFLUORESCENCE; IMMUNOPRECIPITATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; STOMACH TUMOR; TUMOR RESISTANCE; TUMOR XENOGRAFT;

EID: 80054861063     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2011.06.070     Document Type: Article

References (39)

1. Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127:2893-2917.
2. Catalano V, Labianca R, Beretta GD, et al. Gastric cancer. Crit Rev Oncol Hematol 2009;71:127-164.
3. Doi WK, Siena S, Cascinu S, et al. Efficacy, tolerability and pharmacokinetics of gefitinib (ZD1839) in pretreated patients with metastatic gastric cancer. Proc Am Soc Clin Oncol 2003;22:(abstr 1036).
4. Becker JC, Muller-Tidow C, Serve H, et al. Role of receptor tyrosine kinases in gastric cancer: new targets for a selective therapy. World J Gastroenterol 2006;12:3297-3305. (Pubitemid 43933772)
5. Walaas SI, Aswad DW, Greengard P. A dopamine- and cyclic AMPregulated phosphoprotein enriched in dopamine-innervated brain regions. Nature 1983;301:69-71. (Pubitemid 13154466)
6. Mukherjee K, Peng D, Brifkani Z, et al. Dopamine and cAMP regulated phosphoprotein MW 32 kDa is overexpressed in early stages of gastric tumorigenesis. Surgery 2010;148:354-363.
7. El-Rifai W, Smith MF Jr, Li G, et al. Gastric cancers overexpress DARPP-32 and a novel isoform, t-DARPP. Cancer Res 2002;62: 4061-4064. (Pubitemid 34791075)
8. Beckler A, Moskaluk CA, Zaika A, et al. Overexpression of the 32-kilodalton dopamine and cyclic adenosine 3′,5′-monophosphate- regulated phosphoprotein in common adenocarcinomas. Cancer 2003;98:1547-1551. (Pubitemid 37151512)
9. Wang MS, Pan Y, Liu N, et al. Overexpression of DARPP-32 in colorectal adenocarcinoma. Int J Clin Pract 2005;59:58-61. (Pubitemid 40260115)
10. Belkhiri A, Zaika A, Pidkovka N, et al. Darpp-32: a novel antiapoptotic gene in upper gastrointestinal carcinomas. Cancer Res 2005;65:6583-6592. (Pubitemid 41060694)
11. Normanno N, De Luca A, Bianco C, et al. Epidermal growth factor receptor (EGFR) signaling in cancer. Gene 2006;366:2-16. (Pubitemid 43199589)
12. Soltoff SP, Carraway KL 3rd, Prigent SA, et al. ErbB3 is involved in activation of phosphatidylinositol 3-kinase by epidermal growth factor. Mol Cell Biol 1994;14:3550-3558. (Pubitemid 24160762)
13. Baselga J, Swain SM. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer 2009;9:463-475.
14. Wakeling AE, Guy SP, Woodburn JR, et al. ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res 2002;62:5749-5754. (Pubitemid 35204731)
15. Greulich H, Chen TH, Feng W, et al. Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants. PLoS Med 2005; 2:e313.
16. Turke AB, Zejnullahu K, Wu YL, et al. Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell 2010;17:77-88.
17. Ercan D, Zejnullahu K, Yonesaka K, et al. Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor. Oncogene 2010;29:2346-2356.
18. Kobayashi S, Ji H, Yuza Y, et al. An alternative inhibitor overcomes resistance caused by a mutation of the epidermal growth factor receptor. Cancer Res 2005;65:7096-7101. (Pubitemid 41161238)
19. Engelman JA, Zejnullahu K, Mitsudomi T, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007;316:1039-1043. (Pubitemid 46799492)
20. Bean J, Brennan C, Shih JY, et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci U S A 2007;104:20932-20937.
21. Moutinho C, Mateus AR, Milanezi F, et al. Epidermal growth factor receptor structural alterations in gastric cancer. BMC Cancer 2008;8:10.
22. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001;29:e45.
23. Wu JY, Wu SG, Yang CH, et al. Comparison of gefitinib and erlotinib in advanced NSCLC and the effect of EGFR mutations. Lung Cancer 2011;72:205-212.
24. Rojo F, Tabernero J, Albanell J, et al. Pharmacodynamic studies of gefitinib in tumor biopsy specimens from patients with advanced gastric carcinoma. J Clin Oncol 2006;24:4309-4316. (Pubitemid 46630789)
25. Slesak B, Harlozinska A, Porebska I, et al. Expression of epidermal growth factor receptor family proteins (EGFR, c-erbB-2 and c-erbB-3) in gastric cancer and chronic gastritis. Anticancer Res 1998;18:2727-2732. (Pubitemid 28386573)
26. Galizia G, Lieto E, Orditura M, et al. Epidermal growth factor receptor (EGFR) expression is associated with a worse prognosis in gastric cancer patients undergoing curative surgery. World J Surg 2007;31:1458-1468. (Pubitemid 46945355)
27. Sithanandam G, Anderson LM. The ERBB3 receptor in cancer and cancer gene therapy. Cancer Gene Ther 2008;15:413-448. (Pubitemid 351822188)
28. Selvendiran K, Bratasz A, Tong L, et al. NCX-4016, a nitro-derivative of aspirin, inhibits EGFR and STAT3 signaling and modulates Bcl-2 proteins in cisplatin-resistant human ovarian cancer cells and xenografts. Cell Cycle 2008;7:81-88.
29. Prigent SA, Gullick WJ. Identification of c-erbB-3 binding sites for phosphatidylinositol 3'-kinase and SHC using an EGF receptor/cerbB- 3 chimera. EMBO J 1994;13:2831-2841.
30. Guy PM, Platko JV, Cantley LC, et al. Insect cell-expressed p180erbB3 possesses an impaired tyrosine kinase activity. Proc Natl Acad Sci U S A 1994;91:8132-8136.
31. Olayioye MA, Neve RM, Lane HA, et al. The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J 2000;19:3159-3167. (Pubitemid 30428195)
32. Frolov A, Schuller K, Tzeng CW, et al. ErbB3 expression and dimerization with EGFR influence pancreatic cancer cell sensitivity to erlotinib. Cancer Biol Ther 2007;6:548-554. (Pubitemid 47328329)
33. Arteaga CL. HER3 and mutant EGFR meet MET. Nat Med 2007; 13:675-677. (Pubitemid 46889747)
34. Sergina NV, Rausch M, Wang D, et al. Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature 2007;445:437-441. (Pubitemid 46160912)
35. Cappuzzo F, Toschi L, Tallini G, et al. Insulin-like growth factor receptor 1 (IGFR-1) is significantly associated with longer survival in non-small-cell lung cancer patients treated with gefitinib. Ann Oncol 2006;17:1120-1127. (Pubitemid 43985248)
36. Ceresa BP, Bahr SJ. rab7 activity affects epidermal growth factor: epidermal growth factor receptor degradation by regulating endocytic trafficking from the late endosome. J Biol Chem 2006;281: 1099-1106.
37. Ono M, Hirata A, Kometani T, et al. Sensitivity to gefitinib (Iressa, ZD1839) in non-small cell lung cancer cell lines correlates with dependence on the epidermal growth factor (EGF) receptor/extracellular signal-regulated kinase 1/2 and EGF receptor/Akt pathway for proliferation. Mol Cancer Ther 2004;3:465-472. (Pubitemid 39193724)
38. Perez-Torres M, Guix M, Gonzalez A, et al. Epidermal growth factor receptor (EGFR) antibody down-regulates mutant receptors and inhibits tumors expressing EGFR mutations. J Biol Chem 2006; 281:40183-40192. (Pubitemid 46041823)
39. Yang J, Li M, Hong L, et al. Preparation of a novel monoclonal antibody specific to DARPP-32. Hybridoma (Larchmt) 2010;29:351-354.